Compare Ascendis Pharma A/S (ASND) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Oatly Group AB - ADR — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Oatly Group AB - ADR trades at $9.85 (market cap $307.57M). The key difference: Ascendis Pharma A/S is far larger — about 57.7× Oatly Group AB - ADR's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| ASND | OTLY | |
|---|---|---|
Market Cap | $17.74B | $307.57M |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $18.54 |
52-Week Low | $163.32 | $8.03 |
Enterprise Value | $18.11B | $805.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
OTLY trades at $9.85, up 2.82% today, with a bullish technical signal from ADX indicators. Revenue growth is steady, reaching $862M in 2025, but profitability remains elusive with a net income margin of -17.06%. The company continues to burn cash, though the rate has improved from previous years. Recent news includes new product launches in Canada and an upcoming Q2 2026 earnings report on July 22, 2026.
The outlook is mixed: strong brand presence and revenue growth offer potential, but persistent losses, high debt, and negative cash flow pose significant risks. Analyst sentiment is divided, with 44% recommending buy and 50% hold. Investment hinges on OTLY's ability to achieve profitability and manage its cash runway effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
